2.9228
price down icon2.90%   -0.0872
after-market 시간 외 거래: 2.86 -0.0628 -2.15%
loading
전일 마감가:
$3.01
열려 있는:
$2.922
하루 거래량:
4,328
Relative Volume:
0.20
시가총액:
$15.89M
수익:
-
순이익/손실:
$-14.29M
주가수익비율:
-0.5285
EPS:
-5.53
순현금흐름:
$-12.27M
1주 성능:
-12.75%
1개월 성능:
-32.03%
6개월 성능:
-42.65%
1년 성능:
-22.06%
1일 변동 폭
Value
$2.90
$3.00
1주일 범위
Value
$2.865
$3.54
52주 변동 폭
Value
$2.1501
$8.8465

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name
명칭
Aprea Therapeutics Inc
Name
전화
617-463-9385
Name
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Name
직원
7
Name
트위터
Name
다음 수익 날짜
2024-12-07
Name
최신 SEC 제출 서류
Name
APRE's Discussions on Twitter

APRE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
APRE 2.9228 15.89M 0 -14.29M -12.27M -5.53
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2020-12-28 다운그레이드 Robert W. Baird Outperform → Neutral
2020-12-16 개시 Berenberg Buy
2020-09-29 재개 JP Morgan Neutral
2020-06-22 개시 H.C. Wainwright Neutral
2020-04-21 개시 Robert W. Baird Outperform
2019-10-28 개시 JP Morgan Neutral
2019-10-28 개시 Morgan Stanley Equal-Weight
2019-10-28 개시 RBC Capital Mkts Outperform
모두보기

Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스

pulisher
01:44 AM

HC Wainwright Has Bullish Outlook for APRE FY2024 Earnings - Defense World

01:44 AM
pulisher
Nov 20, 2024

Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World

Nov 20, 2024
pulisher
Nov 11, 2024

Aprea Therapeutics (NASDAQ: APRE) Announces Financial Results and Corporate Updates - Defense World

Nov 11, 2024
pulisher
Nov 10, 2024

Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 10, 2024
pulisher
Nov 10, 2024

Health Catalyst signs definitive agreement to acquire Intraprise Health - MSN

Nov 10, 2024
pulisher
Nov 07, 2024

Aprea Therapeutics Inc (APRE) Quarterly 10-Q Report - Quartz

Nov 07, 2024
pulisher
Nov 07, 2024

Aprea Therapeutics Inc (APRE) Q3 2024 Earnings: Revenue Hits $0. - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo

Oct 31, 2024
pulisher
Oct 29, 2024

Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN

Oct 29, 2024
pulisher
Oct 28, 2024

DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR

Oct 28, 2024
pulisher
Oct 27, 2024

Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews

Oct 27, 2024
pulisher
Oct 26, 2024

Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World

Oct 26, 2024
pulisher
Oct 26, 2024

Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa

Oct 26, 2024
pulisher
Oct 25, 2024

Aprea therapeutics director sells shares worth $29,583 - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Aprea therapeutics CEO Gilad Oren buys $1,957 in stock - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Aprea Therapeutics presents preliminary results on APR-1051 - Yahoo Finance

Oct 24, 2024
pulisher
Oct 24, 2024

Aprea therapeutics CEO Gilad Oren buys $1,957 in stock By Investing.com - Investing.com UK

Oct 24, 2024
pulisher
Oct 23, 2024

Insider Spends US$132k Buying More Shares In Aprea Therapeutics - Yahoo Finance

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations - Seeking Alpha

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea reports safe trial results for new cancer drug - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea reports safe trial results for new cancer drug By Investing.com - Investing.com UK

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR - EIN News

Oct 23, 2024
pulisher
Oct 20, 2024

Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock - Simply Wall St

Oct 20, 2024
pulisher
Oct 17, 2024

Aprea therapeutics director Duey Marc acquires $131,700 in stock By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea therapeutics director Duey Marc acquires $131,700 in stock - Investing.com India

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea Therapeutics CEO Gilad Oren buys $725 in common stock By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea therapeutics CFO John Hamill acquires shares worth $123 - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea Therapeutics CEO Gilad Oren buys $725 in common stock - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

Aprea Therapeutics director Duey Marc buys $490 in stock - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea therapeutics CFO John Hamill acquires shares worth $123 By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea Therapeutics director Duey Marc buys $490 in stock By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates - MSN

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea therapeutics director Bernd Seizinger buys $26,800 in stock By Investing.com - Investing.com Australia

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea Therapeutics president Gilad Oren buys $2,971 in stock - Investing.com India

Oct 16, 2024
pulisher
Oct 15, 2024

Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MyChesCo

Oct 15, 2024
pulisher
Oct 15, 2024

Aprea therapeutics CFO John Hamill buys $1,174 in common stock By Investing.com - Investing.com South Africa

Oct 15, 2024
pulisher
Oct 15, 2024

Aprea therapeutics director Bernd Seizinger buys $26,800 in stock - Investing.com India

Oct 15, 2024
pulisher
Oct 15, 2024

Aprea Therapeutics president Gilad Oren buys $2,971 in stock By Investing.com - Investing.com Canada

Oct 15, 2024

Aprea Therapeutics Inc (APRE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
자본화:     |  볼륨(24시간):